Alisporivir - A Host-Targeting Antiviral, Provides Low Viral Breakthrough Rate And High Barrier To Resistance In Hcv Genotype 1 Treatment-Naive Patients In The Phase Iib Essential Study
62Nd Annual Meeting of the American-Association-For-The-Study-Of-Liver-Diseases (Aasld), Date: NOV 04-08, 2011, Location: San Francisco, CA, Patrocinadores: Amer Assoc Study Liver Dis
